These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 35956875)
1. Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases. Yue Q; Song Y; Liu Z; Zhang L; Yang L; Li J Molecules; 2022 Aug; 27(15):. PubMed ID: 35956875 [TBL] [Abstract][Full Text] [Related]
2. Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior. Leerach N; Harashima A; Munesue S; Kimura K; Oshima Y; Goto H; Yamamoto H; Higashida H; Yamamoto Y Glycoconj J; 2021 Jun; 38(3):303-310. PubMed ID: 33108607 [TBL] [Abstract][Full Text] [Related]
3. The RAGE signaling in osteoporosis. Zhou J; Liu S; Bi S; Kong W; Qian R; Xie X; Zeng M; Jiang X; Liao Z; Shuai M; Liu W; Cheng L; Wu M Biomed Pharmacother; 2023 Sep; 165():115044. PubMed ID: 37354815 [TBL] [Abstract][Full Text] [Related]
4. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease. Prasad K Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281 [TBL] [Abstract][Full Text] [Related]
5. AGEs, RAGEs and s-RAGE; friend or foe for cancer. Ahmad S; Khan H; Siddiqui Z; Khan MY; Rehman S; Shahab U; Godovikova T; Silnikov V; Moinuddin Semin Cancer Biol; 2018 Apr; 49():44-55. PubMed ID: 28712719 [TBL] [Abstract][Full Text] [Related]
6. Targeting RAGE Signaling in Inflammatory Disease. Hudson BI; Lippman ME Annu Rev Med; 2018 Jan; 69():349-364. PubMed ID: 29106804 [TBL] [Abstract][Full Text] [Related]
7. RAGE and its ligands: from pathogenesis to therapeutics. Jangde N; Ray R; Rai V Crit Rev Biochem Mol Biol; 2020 Dec; 55(6):555-575. PubMed ID: 32933340 [TBL] [Abstract][Full Text] [Related]
8. The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases. Delrue C; Speeckaert R; Delanghe JR; Speeckaert MM Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769213 [TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Singh H; Agrawal DK Drug Dev Res; 2022 Sep; 83(6):1257-1269. PubMed ID: 35781678 [TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway. Ren L; Lou Y; Sun M Bioengineered; 2021 Dec; 12(1):5985-5995. PubMed ID: 34477479 [TBL] [Abstract][Full Text] [Related]
12. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. Yan SF; Ramasamy R; Schmidt AM J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073 [TBL] [Abstract][Full Text] [Related]
13. The RAGE/multiligand axis: a new actor in tumor biology. Rojas A; Schneider I; Lindner C; Gonzalez I; Morales MA Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35727208 [TBL] [Abstract][Full Text] [Related]
14. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment. Gasparotto J; Girardi CS; Somensi N; Ribeiro CT; Moreira JCF; Michels M; Sonai B; Rocha M; Steckert AV; Barichello T; Quevedo J; Dal-Pizzol F; Gelain DP J Biol Chem; 2018 Jan; 293(1):226-244. PubMed ID: 29127203 [TBL] [Abstract][Full Text] [Related]
15. Activation of the receptor for advanced glycation end products and consequences on health. Wautier MP; Guillausseau PJ; Wautier JL Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394 [TBL] [Abstract][Full Text] [Related]
16. Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors. Kim HJ; Jeong MS; Jang SB Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199060 [TBL] [Abstract][Full Text] [Related]
17. Ousting RAGE in melanoma: A viable therapeutic target? Syed DN; Aljohani A; Waseem D; Mukhtar H Semin Cancer Biol; 2018 Apr; 49():20-28. PubMed ID: 29079306 [TBL] [Abstract][Full Text] [Related]
18. The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease. Sharma A; Kaur S; Sarkar M; Sarin BC; Changotra H Clin Rev Allergy Immunol; 2021 Apr; 60(2):244-258. PubMed ID: 33170477 [TBL] [Abstract][Full Text] [Related]
19. The dynamic roles of advanced glycation end products. Khalid M; Adem A Vitam Horm; 2024; 125():1-29. PubMed ID: 38997161 [TBL] [Abstract][Full Text] [Related]
20. The receptor for advanced glycation end-products enhances lung epithelial wound repair: An in vitro study. Zhai R; Blondonnet R; Ebrahimi E; Belville C; Audard J; Gross C; Choltus H; Henrioux F; Constantin JM; Pereira B; Blanchon L; Sapin V; Jabaudon M Exp Cell Res; 2020 Jun; 391(2):112030. PubMed ID: 32330509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]